Kura Oncology, Inc. (NASDAQ:KURA) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 7.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 3,924,448 shares of the company's stock after acquiring an additional 275,173 shares during the period. Vanguard Group Inc. owned 5.28% of Kura Oncology worth $35,791,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Tower Research Capital LLC TRC raised its position in Kura Oncology by 46.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,710 shares of the company's stock valued at $50,000 after purchasing an additional 1,501 shares during the last quarter. Royal Bank of Canada raised its holdings in Kura Oncology by 81.5% in the 2nd quarter. Royal Bank of Canada now owns 6,801 shares of the company's stock valued at $72,000 after buying an additional 3,053 shares during the last quarter. Pale Fire Capital SE acquired a new stake in Kura Oncology during the 3rd quarter worth approximately $92,000. E Fund Management Co. Ltd. lifted its holdings in shares of Kura Oncology by 12.2% in the 3rd quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company's stock worth $109,000 after purchasing an additional 1,301 shares in the last quarter. Finally, Point72 Middle East FZE bought a new stake in Kura Oncology during the 4th quarter valued at $115,000.

Analyst Ratings Changes

KURA has been the subject of several recent research reports. JMP Securities boosted their target price on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a "market outperform" rating in a research report on Wednesday, January 31st. HC Wainwright restated a "buy" rating and set a $32.00 price objective on shares of Kura Oncology in a report on Wednesday, March 6th. StockNews.com raised shares of Kura Oncology from a "sell" rating to a "hold" rating in a research report on Wednesday, April 3rd. Mizuho started coverage on Kura Oncology in a report on Friday, December 22nd. They set a "buy" rating and a $26.00 price objective for the company. Finally, Wedbush reissued an "outperform" rating and issued a $37.00 target price on shares of Kura Oncology in a research report on Wednesday, February 28th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $28.28.

Kura Oncology Price Performance

Shares of Kura Oncology stock traded up $0.50 during trading on Thursday, hitting $20.40. 763,773 shares of the stock traded hands, compared to its average volume of 1,375,424. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52 week low of $7.41 and a 52 week high of $24.17. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -9.81 and a beta of 0.85. The firm's fifty day moving average is $21.04 and its 200-day moving average is $14.78.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same quarter in the prior year, the company earned ($0.49) EPS. Research analysts expect that Kura Oncology, Inc. will post -2.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kura Oncology news, CEO Troy Edward Wilson sold 91,052 shares of Kura Oncology stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total value of $1,841,981.96. Following the completion of the transaction, the chief executive officer now directly owns 559 shares of the company's stock, valued at $11,308.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Kathleen Ford sold 1,496 shares of the business's stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the transaction, the chief operating officer now directly owns 21,602 shares of the company's stock, valued at $384,515.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Troy Edward Wilson sold 91,052 shares of the firm's stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $20.23, for a total transaction of $1,841,981.96. Following the completion of the sale, the chief executive officer now owns 559 shares in the company, valued at approximately $11,308.57. The disclosure for this sale can be found here. In the last 90 days, insiders sold 96,919 shares of company stock worth $1,946,415. 5.60% of the stock is currently owned by company insiders.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.